Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine, Lymph Nodes, Lymphoid Tissue
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis against AIDS-related opportunistic infections. Supportive therapies, such as medications for nausea, vomiting, anemia, and analgesia. Patients must have: HIV infection. CD4 count 100 - 500 cells/mm3. At least two palpable lymph nodes. Plasma viremia. No CURRENT AIDS-defining conditions. No prior antiretroviral treatment. Exclusion Criteria Concurrent Medication: Excluded during the first 8 weeks of study: Other antiretroviral agents. Steroids. Interleukins. Interferons. Cytotoxic chemotherapy. Prior Medication: Excluded: Prior antiretroviral therapy. Prior cytotoxic chemotherapy. Acute therapy for an infection or another medical illness within 14 days prior to study entry.
Sites / Locations
- Cedars Sinai Med Ctr
- Palo Alto Veterans Affairs Health Care System
- AIDS Community Research Consortium
- Mount Zion Med Ctr / UCSF
- North Broward Hosp District
- Goodgame Med Group
- Univ of Illinois
- Univ of Texas Southwestern Med Ctr of Dallas
- Baylor College of Medicine / Houston Veterans Adm Med Ctr